New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
08:58 EDTACORAcorda Therapeutics delays start of Phase 3 study of dalfampridine-QD to 2H
Acorda Therapeutics announced that the initiation of its Phase 3 study of dalfampridine-QD in people with post-stroke walking deficits will begin in the second half of 2014; previously the company had projected study initiation in the second quarter of 2014. The developer of the once-daily, or QD, formulation has informed the company of an alcohol dose dumping finding in vitro and the company will need to perform a short clinical study to determine whether this also exists in vivo. The clinical study will be conducted in healthy volunteers and is expected to be completed in the third quarter of 2014, Acorda said.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
09:20 EDTACORCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 22, 2015
07:33 EDTACORAcorda Therapeutics presents data on remyelinating anibody clinical study
Subscribe for More Information
07:19 EDTACORAcorda Therapeutics assumed with a Neutral at Piper Jaffray
Subscribe for More Information
April 20, 2015
14:32 EDTACORPharmacyclics patent for Imbruvica challenged by Hayman Capital's Bass
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use